Q-omics provides the consensus-scored TEAD4 profile across patient tissues and cancer cell-line models. TEAD4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TEAD4 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, TEAD4 RNA expression shows 16,633 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where TEAD4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TEAD4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TEAD4 survival associations across molecular data types. TEAD4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TEAD4 RNA expression–survival associations across cancer types. High TEAD4 expression shows unfavorable associations in ACC, UVM, KIRC, PAAD and LGG, but favorable associations in STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TEAD4 RNA expression.
This table summarizes TEAD4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TEAD4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TEAD4 shows lower tumor expression in THCA and higher tumor expression in COAD, HNSC, KIRC, STAD and BLCA. The COAD box plot shows higher TEAD4 RNA expression in tumor versus normal tissue (log2 FC = +2.893, t-test p < 0.001).
This table shows molecular features associated with TEAD4 in patient tissues and cancer cell lines. In patient samples, TEAD4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TEAD4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
